BP Equities Q3FY26 Result Update Carysil Ltd.
BP Wealth
...
| Summary | Date | Stock | Author | LTP | Target | Price at reco (Change since reco%) |
Upside(%) | Type | Report | Discuss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 06 Feb 2026 | Carysil |
BP Wealth
|
952.20 | 932.40 (2.12%) |
Results Update
|
||||||
| 05 Feb 2026 | CCL Products |
BP Wealth
|
1026.30 | 990.00 (3.67%) |
Results Update
|
||||||
| 05 Feb 2026 | Godrej Agrovet |
BP Wealth
|
575.85 | 553.75 (3.99%) |
Results Update
|
||||||
| 04 Feb 2026 | Mankind Pharma |
BP Wealth
|
2081.00 | 2089.30 (-0.40%) |
Results Update
|
||||||
| 04 Feb 2026 | Zydus Wellness |
BP Wealth
|
406.30 | 401.25 (1.26%) |
Results Update
|
||||||
| 03 Feb 2026 | UPL |
BP Wealth
|
744.35 | 739.80 (0.62%) |
Results Update
|
||||||
| 03 Feb 2026 | Automobiles & Auto Components |
BP Wealth
|
Sector Update
|
||||||||
| 02 Feb 2026 | Ambuja Cements |
BP Wealth
|
538.55 | 510.50 (5.49%) |
Results Update
|
||||||
| 30 Jan 2026 | GHCL |
BP Wealth
|
517.00 | 530.70 (-2.58%) |
Results Update
|
||||||
| 30 Jan 2026 | ASK Automotive |
BP Wealth
|
458.05 | 445.95 (2.71%) |
Results Update
|
||||||
| 30 Jan 2026 | Dabur |
BP Wealth
|
511.00 | 506.60 (0.87%) |
Results Update
|
||||||
| 29 Jan 2026 | Maruti Suzuki |
BP Wealth
|
15011.00 | 14502.00 (3.51%) |
Results Update
|
||||||
| 29 Jan 2026 | Manorama Industries |
BP Wealth
|
1437.60 | 1375.80 (4.49%) |
Results Update
|
||||||
| 28 Jan 2026 | Marico |
BP Wealth
|
754.75 | 736.65 (2.46%) |
Results Update
|
||||||
| 27 Jan 2026 | UltraTech Cement |
BP Wealth
|
12920.00 | 12589.00 (2.63%) |
Results Update
|
||||||
| 25 Jan 2026 | Gujarat Themis |
BP Wealth
|
335.20 | 367.00 | 315.65 (6.19%) | 9.49 |
Buy
|
Gujarat Themis Biosyn Limited Tgt 367
BP Wealth
Gujarat Themis Biosyn Limited (GTBL), incorporated in 1981, is an Indian pharmaceutical company specialising in the manufacturing of fermentation-based pharmaceutical intermediates and APIs. The company focuses on niche and critical intermediates, primarily Rifamycin S and Rifamycin O, which are key inputs for Rifampicin and Rifaximin antibiotics widely used in the treatment of tuberculosis and bacterial infections. GTBL operates state-of-the-art fermentation facilities at Vapi with an expanded installed capacity of ~990 KL, enabling scalable production with high cost efficiency, consistent quality, and operational flexibility across multiple fermentation products. The niche nature of Rifamycin intermediates used in critical therapies such as tuberculosis ensures stable demand and strategic importance. Additionally, the company's ongoing investments in R&D, new molecule development, and forward integration into APIs further reinforce its positioning by deepening technical complexity and customer stickiness. The company previously considered a merger with Themis...
|
|||
| 24 Jan 2026 | Godrej Consumer Products |
BP Wealth
|
1185.00 | 1240.40 (-4.47%) |
Results Update
|
||||||
| 22 Jan 2026 | Dalmia Bharat |
BP Wealth
|
2161.10 | 2143.70 (0.81%) |
Results Update
|
||||||
| 21 Jan 2026 | SRF |
BP Wealth
|
2975.70 | 2676.90 (11.16%) |
Results Update
|
||||||
| 20 Jan 2026 | JK Cement |
BP Wealth
|
5906.50 | 5891.50 (0.25%) |
Results Update
|
||||||
|
more
loading
|
|||||||||||